Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

Scilex Holding Company

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PALO ALTO, CALIF., JULY 07, 2026 (GLOBE NEWSWIRE) -- SEMNUR PHARMACEUTICALS, INC. (SEMNUR OR THE COMPANY) (OTC: SMNR) , A CLINICAL LATE-STAGE SPECIALTY PHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF NOVEL NON-OPIOID PAIN THERAPIES, TODAY ANNOUNCED THE SIGNING OF A BINDING TERM SHEET WITH IHOLDING GROUP LLP (IHOLDING), A PRIVATE INVESTMENT GROUP HEADQUARTERED IN ALMATY, REPUBLIC OF KAZAKHSTAN. THE TERM SHEET CONTEMPLATES THAT IHOLDING WILL PURCHASE $100,000,000 OF NEWLY ISSUED SHARES OF SEMNUR COMMON STOCK. THE PURCHASE PRICE FOR SUCH SHARES IS EXPECTED TO BE $10.00 PER SHARE, WHICH WOULD REPRESENT APPROXIMATELY 10,000,000 SHARES.

SEMNUR PHARMACEUTICALS, INC. (SEMNUR), A MAJORITY-OWNED SUBSIDIARY OF SCILEX HOLDING COMPANY (NASDAQ: SCLX, SCILEX), ANNOUNCES SIGNING OF BINDING TERM SHEET FOR PROPOSED $100 MILLION STRATEGIC INVESTMENT FROM IHOLDING GROUP LLP

PALO ALTO, CALIF., JULY 06, 2026 (GLOBE NEWSWIRE) -- SCILEX HOLDING COMPANY (SCILEX OR THE COMPANY) (NASDAQ: SCLX), AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING, AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN AND NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, TODAY ANNOUNCED THAT THE DREAM BOWL I MEME COIN TOKENS (DREAM BOWL TOKENS) COMMENCE TRADING ON THE BICONOMY EXCHANGE ON JULY 6, 2026.

SCILEX HOLDING COMPANY ANNOUNCES DREAM BOWL I MEME COIN TOKENS COMMENCE TRADING ON THE BICONOMY EXCHANGE ON JULY 6, 2026

PALO ALTO, CALIF., JULY 06, 2026 (GLOBE NEWSWIRE) -- SCILEX HOLDING COMPANY (SCILEX OR THE COMPANY) (NASDAQ: SCLX), AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING, AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN AND NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, TODAY ANNOUNCED THE SIGNING OF A BINDING TERM SHEET WITH IHOLDING GROUP LLP ("IHOLDING"), A PRIVATE INVESTMENT GROUP HEADQUARTERED IN ALMATY, REPUBLIC OF KAZAKHSTAN. THE TERM SHEET CONTEMPLATES THAT IHOLDING WILL PURCHASE $100,000,000 OF NEWLY ISSUED SHARES OF SCILEX COMMON STOCK. THE PURCHASE PRICE FOR SUCH SHARES IS EXPECTED TO BE $15.00 PER SHARE, WHICH WOULD REPRESENT APPROXIMATELY 6,666,667 SHARES.

SCILEX HOLDING COMPANY ANNOUNCES SIGNING OF BINDING TERM SHEET FOR PROPOSED $100 MILLION STRATEGIC INVESTMENT FROM IHOLDING GROUP LLP

SIGNIFICANT APPRECIATION IN ALPHA TAU (NASDAQ: DRTS) POSITION (UP ~$128 MILLION) SCILEX (NASDAQ: SCLX) LOAN SUBSTANTIALLY REPAID TOTAL CASH AND ASSETS BUILD TO APPROXIMATELY $270 MILLION (AS OF MARCH 31, 2026, AFTER THE $10.5 MILLION DIVIDEND PAID IN JANUARY 2026) ORAMED TO JOIN THE RUSSELL 2000 AND RUSSELL 3000 INDEXES THIS WEEK NEW YORK, JUNE 25, 2026 /PRNEWSWIRE/ --ORAMED PHARMACEUTICALS INC. (NASDAQ: ORMP) (TASE: ORMP) ("ORAMED" OR THE "COMPANY" OR "WE"), A DIVERSIFIED OPERATING COMPANY, TODAY ISSUED THE FOLLOWING LETTER TO SHAREHOLDERS FROM ITS CHIEF EXECUTIVE OFFICER, NADAV KIDRON. THE LETTER HIGHLIGHTS THE COMPANY'S ADDITION TO THE RUSSELL 2000 AND RUSSELL 3000 INDEXES, THE SUBSTANTIAL REPAYMENT OF ITS SCILEX LOAN, AND A STRENGTHENED BALANCE SHEET OF APPROXIMATELY $270 MILLION IN TOTAL CASH AND ASSETS, AS OF MARCH 31, 2026 (UNAUDITED).

ORAMED RELEASES LETTER TO SHAREHOLDERS, HIGHLIGHTING RUSSELL 2000/3000 INDEX INCLUSION, SCILEX LOAN REPAYMENT, STRATEGIC PORTFOLIO APPRECIATION, AND A STRENGTHENED BALANCE SHEET

PALO ALTO, CALIF., JUNE 16, 2026 (GLOBE NEWSWIRE) -- SCILEX HOLDING COMPANY (SCILEX OR THE COMPANY) (NASDAQ: SCLX), AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING, AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN AND NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, TODAY ANNOUNCED DREAM BOWL I MEME COIN TOKENS (DREAM BOWL TOKENS) TO LIST ON BICONOMY EXCHANGE AS EARLY AS JUNE 23, 2026.

SCILEX HOLDING COMPANY ANNOUNCES DREAM BOWL I MEME COIN TOKENS TO LIST ON BICONOMY EXCHANGE AS EARLY AS JUNE 23, 2026

PALO ALTO, CALIF., JUNE 12, 2026 (GLOBE NEWSWIRE) -- SCILEX HOLDING COMPANY (SCILEX OR THE COMPANY) (NASDAQ: SCLX), AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING, AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN AND NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, TODAY CONFIRMED THE PREVIOUSLY ANNOUNCED PAYMENT DATE OF JUNE 15, 2026 (THE PAYMENT DATE) FOR THE DIVIDEND OF SEMNUR PHARMACEUTICALS, INC. (SEMNUR) (OTC: SMNR) COMMON STOCK HELD BY THE COMPANY TO ITS STOCKHOLDERS AND CERTAIN OTHER ELIGIBLE HOLDERS OF SCILEX SECURITIES (COLLECTIVELY, THE PARTICIPATING HOLDERS) THAT HELD SUCH SECURITIES AS OF THE RECORD DATE FOR THE DIVIDEND, WHICH IS JUNE 1, 2026 (THE RECORD DATE). NASDAQ HAS DETERMINED THE EX-DIVIDEND DATE TO BE ON JUNE 16, 2026.

SCILEX HOLDING COMPANY (SCILEX) CONFIRMS THE PREVIOUSLY ANNOUNCED PAYMENT DATE OF JUNE 15, 2026 FOR THE DIVIDEND OF SEMNUR PHARMACEUTICALS, INC. COMMON STOCK TO HOLDERS OF SCILEX COMMON STOCK AND OTHER ELIGIBLE EQUITY SECURITIES

PALO ALTO, CALIF., JUNE 04, 2026 (GLOBE NEWSWIRE) -- SCILEX HOLDING COMPANY (SCILEX OR THE COMPANY) (NASDAQ: SCLX), AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING, AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN AND NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS (THE BOARD) HAS SET JUNE 15, 2026 AS THE PAYMENT DATE (THE PAYMENT DATE) FOR THE PREVIOUSLY ANNOUNCED DIVIDEND OF SEMNUR PHARMACEUTICALS, INC. (SEMNUR) (OTC: SMNR) COMMON STOCK HELD BY THE COMPANY TO ITS STOCKHOLDERS AND CERTAIN OTHER ELIGIBLE HOLDERS OF SCILEX SECURITIES (COLLECTIVELY, THE PARTICIPATING HOLDERS) THAT HELD SUCH SECURITIES AS OF THE RECORD DATE FOR THE DIVIDEND, WHICH IS JUNE 1, 2026 (THE RECORD DATE). NASDAQ WILL DETERMINE THE EX-DIVIDEND DATE IN ACCORDANCE WITH THEIR RULES.

SCILEX HOLDING COMPANY (SCILEX) ANNOUNCES A PAYMENT DATE OF JUNE 15, 2026 FOR THE PREVIOUSLY ANNOUNCED DIVIDEND OF SEMNUR PHARMACEUTICALS, INC. COMMON STOCK TO HOLDERS OF SCILEX COMMON STOCK AND OTHER ELIGIBLE EQUITY SECURITIES

PALO ALTO, CALIF., MAY 22, 2026 (GLOBE NEWSWIRE) -- SCILEX HOLDING COMPANY (SCILEX OR THE COMPANY) (NASDAQ: SCLX), AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING, AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN AND NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS (THE BOARD) APPROVED A DIVIDEND OF SEMNUR PHARMACEUTICALS, INC. (SEMNUR) (OTC: SMNR) COMMON STOCK HELD BY THE COMPANY TO ITS STOCKHOLDERS AND CERTAIN OTHER ELIGIBLE EQUITYHOLDERS OF SCILEX (COLLECTIVELY, THE PARTICIPATING HOLDERS). THE RECORD DATE FOR THE DIVIDEND IS JUNE 1, 2026 (THE RECORD DATE).

SCILEX HOLDING COMPANY (SCILEX) ANNOUNCES ITS BOARD OF DIRECTORS APPROVED A DIVIDEND OF SEMNUR PHARMACEUTICALS, INC. COMMON STOCK TO HOLDERS OF SCILEX COMMON STOCK AND OTHER ELIGIBLE EQUITY SECURITIES WITH A RECORD DATE OF JUNE 1, 2026

PALO ALTO, CALIF., MAY 05, 2026 (GLOBE NEWSWIRE) -- SCILEX HOLDING COMPANY (SCILEX OR THE COMPANY) (NASDAQ: SCLX), AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING, AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN AND NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, TODAY ANNOUNCED THAT ITS INDIRECT SUBSIDIARY, ACEA THERAPEUTICS, INC, AN EXEMPTED COMPANY INCORPORATED WITH LIMITED LIABILITY IN THE CAYMAN ISLANDS (ACEA THERA), ACEA PHARMA, INC., AN EXEMPTED COMPANY INCORPORATED WITH LIMITED LIABILITY IN THE CAYMAN ISLANDS AND WHOLLY OWNED SUBSIDIARY OF ACEA THERA (ACEA PHARMA), AND PHOENIX ASIA HOLDINGS LIMITED, A COMPANY ORGANIZED UNDER THE LAWS OF THE CAYMAN ISLANDS (PHOENIX) (NASDAQ: PHOE), ENTERED INTO A STOCK ACQUISITION AGREEMENT PURSUANT TO WHICH ACEA THERA AGREED TO TRANSFER AND SELL, AND PHOENIX AGREED TO PURCHASE, 100% OF THE ISSUED AND OUTSTANDING EQUITY INTERESTS OF ACEA PHARMA IN EXCHANGE FOR THE DELIVERY TO ACEA THERA OF 100,000,000 NEWLY-ISSUED ORDINARY SHARES AT $10.00 PER SHARE, PAR VALUE $0.00001 PER SHARE, OF PHOENIX (THE ACQUISITION), THE VALUE OF WHICH WAS AS AGREED BY THE PARTIES TO BE $1,000,000,000.

SCILEX HOLDING COMPANY ANNOUNCES ITS SUBSIDIARIES, ACEA THERAPEUTICS, INC. AND ACEA PHARMA, INC., ENTERED INTO A DEFINITIVE AGREEMENT WITH PHOENIX ASIA HOLDINGS LIMITED

PALO ALTO, CALIF., MAY 04, 2026 (GLOBE NEWSWIRE) -- SCILEX HOLDING COMPANY (SCILEX OR THE COMPANY) (NASDAQ: SCLX), AN INNOVATIVE REVENUE-GENERATING COMPANY FOCUSED ON ACQUIRING, DEVELOPING, AND COMMERCIALIZING NON-OPIOID PAIN MANAGEMENT PRODUCTS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN AND NEURODEGENERATIVE AND CARDIOMETABOLIC DISEASE, TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS (THE BOARD) FIXED MAY 26, 2026 (THE PAYMENT DATE) AS THE DATE ON WHICH THE PREVIOUSLY ANNOUNCED DIVIDEND (THE DIVIDEND) OF DREAM BOWL MEME COIN I TOKENS HELD BY THE COMPANY (THE DREAM BOWL TOKENS) WILL BE PAID TO ITS RECORD STOCKHOLDERS AND CERTAIN OTHER ELIGIBLE EQUITYHOLDERS OF SCILEX (COLLECTIVELY, THE RECORD HOLDERS) AS OF THE CLOSE OF BUSINESS ON APRIL 30, 2026 (THE RECORD DATE).

SCILEX HOLDING COMPANY ANNOUNCES ITS BOARD OF DIRECTORS APPROVED MAY 26, 2026 AS THE PAYMENT DATE OF THE PREVIOUSLY ANNOUNCED DIVIDEND OF DREAM BOWL MEME COIN I TOKENS TO RECORD HOLDERS OF COMMON STOCK AND OTHER ELIGIBLE EQUITY SECURITIES AS OF THE RECORD DATE OF APRIL 30, 2026

Scilex Holding Company

SCLX

Price

Financial Reports

No items found.

Press Releases

Scilex Holding Company

SCLX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

SCLX